Clinical Trial

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

Study acronym: BELLINI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2019-01-22; most recent amendment 2024-05-28.
Status change: Not Yet Recruiting → Recruiting 2019-10-23
Trial Details
NCT Number NCT03815890
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Bristol-Myers Squibb
Conditions Breast Cancer
Enrollment 80 participants
Start Date 2019-10-04
Primary Completion 2031-01-01 (estimated)
Study Completion 2033-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-30